- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02285244
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
A Phase 2 Feasibility Study of Sotrastaurin for Relapsed and Refractory CLL/SLL/PLL/RT
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the objective clinical response rate of AEB071 (sotrastaurin acetate) treatment in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)/prolymphocytic leukemia (PLL)/Richter's transformation (RT).
SECONDARY OBJECTIVES:
I. To determine the feasibility and tolerability of long-term administration of a fixed dose of AEB071 in patients with relapsed or refractory CLL/SLL/PLL.
II. To examine select downstream pharmacodynamic effects in this population of patients after receiving AEB071 including assessment of the wingless-type MMTV integration site family (WNT) signaling pathway.
III. To determine the feasibility and tolerability of AEB071 treatment in patients with relapsed or refractory mantle cell lymphoma (MCL) as well as to gain preliminary data regarding efficacy in this patient population.
TERTIARY OBJECTIVES:
I. Determine the proportion of patients with select germline and somatic deoxyribonucleic acid (DNA) alterations, including in the B-cell receptor (BCR) pathway.
II. Determine how mutational and transcriptional status in key genes affects response to this therapy and may have affected response to prior therapies.
OUTLINE:
Patients receive sotrastaurin acetate orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then at least every 3 months thereafter.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Life expectancy >= 2 months
Appropriate histologic diagnosis (a) or (b):
(a) Histologically documented diagnosis of intermediate or high risk CLL/SLL, B-PLL, and RT arising from CLL/SLL according to the 2008 guidelines, meeting criteria for active disease requiring treatment:
- Evidence of marrow failure as manifested by the development or worsening of anemia or thrombocytopenia (not attributable to autoimmune hemolytic anemia or thrombocytopenia)
- Massive (>= 6 cm below the costal margin), progressive or symptomatic splenomegaly
- Massive nodes (>= 10 cm) or progressive or symptomatic lymphadenopathy
- Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy
Constitutional symptoms including any of the following:
- Unintentional weight loss of 10% or more within 6 mos.
- Significant fatigue limiting activity
- Fevers >= 100.5 degrees F for 2 weeks or more without evidence of infection
- Night sweats > 1 month without evidence of infection
- Need for cytoreduction prior to stem cell transplantation
- (b) Pathologically documented MCL [defined as either t(11;14) or overexpression of cyclin D1] for the MCL pilot study
- Relapsed after or refractory to at least one prior therapy
- Willingness to undergo all study-related evaluations and procedures
- Ability to understand and willingness to execute a written informed consent document
Exclusion Criteria:
Prior therapy as follows:
- Major surgery within 2 weeks
- Corticosteroids greater than 20 mg/day prednisone (or equivalent) within 2 weeks unless used by inhalation or topical route, or unless necessary for premedication before iodinated contrast dye, or for autoimmune hemolytic anemia
- Cytotoxic chemotherapy or biologic therapy within 4 weeks, excepting BCR kinase inhibitors for which no wash out is required, or
- Nitrosoureas within the 6 weeks of the planned first dose of the study drug
- Failure to recover toxicity from prior chemo- or radiotherapy to grade 1
- Known active leukemia or lymphoma of the central nervous system (CNS) requiring therapy
- Inadequate bone marrow function/hematopoietic reserve, except in the case of documented bone-marrow involvement: absolute neutrophil count (ANC) < 1 x 10^9/L
- Inadequate bone marrow function/hematopoietic reserve, except in the case of documented bone-marrow involvement: platelets < 30 x 10^9/L
- Serum total bilirubin > 2 x ULN (upper limit of normal)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN, or > 5 x ULN if CLL/lymphoma is present in the liver
- Estimated glomerular filtration rate (GFR) < 30 mL/min
- Patients who are receiving treatment with medications that are known to be strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) and CYP3A4/5 substrates with QT prolongation risk that cannot be discontinued prior to study entry
Clinically significant cardiac diseases, including any of the following:
- History or presence of ventricular tachyarrhythmia
- Presence of unstable/uncontrolled atrial fibrillation (with ventricular rate > 100 beats per minute [bpm]); patients with stable atrial fibrillation are eligible provided that they do not meet any of the other exclusion criteria
- Angina pectoris or acute myocardial infarction within 3 months of starting study drug
- New York Heart Association (NYHA) functional class III or IV heart failure
- Labile or uncontrolled hypertension
- History of another malignancy that limits survival to less than 2 years in the estimate of the investigator; basal and squamous cell cancers of the skin, or squamous cell carcinoma of the cervix in situ, which were completely resected or otherwise cured, or localized prostate cancer (Gleason < 5) are eligible
- Gastrointestinal dysfunction, including motility or malabsorption syndromes or inflammatory bowel disease which could limit absorption of AEB071
- Known human immunodeficiency virus (HIV) positivity, or active hepatitis B or C infection with detectible viral nucleic acid in the blood; testing for these viruses is not a required part of screening
- Severe systemic infections requiring intravenous antibiotics within the two weeks prior to initiation of AEB071
- Lactating or pregnant
Women of child-bearing potential or male partners of women of child-bearing potential who will not agree to use highly effective method of contraception throughout the entire study period and for a minimum of 5 terminal half-lives of AEB071 (approximately 36 hours) after the last dose of study drug; highly effective contraception methods include:
- Total abstinence or
- Male or female sterilization or
Combination of any two of the following (a+b or a+c or b+c):
- a. Use of oral, injected or implanted hormonal methods of contraception
- b. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
- c. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential
- Any other life-threatening illness or medical condition that, in the opinion of the investigator, could compromise the safety of the patient or interfere with analysis of study endpoints
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (sotrastaurin acetate)
Patients receive sotrastaurin acetate PO BID on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of CLL/SLL/PLL/RT patients who achieve an objective clinical response, estimated by the number of complete, partial, or partial responses with lymphocytosis divided by the total number of evaluable patients
Time Frame: Up to 9 months
|
Categories of response for CLL and PLL patients defined according to criteria published by the International Workshop on CLL.
Response for SLL/RT patients will be according to revised response criteria for malignant lymphoma.
The objective response rate for all evaluable patients in the phase II study will be calculated with an exact 95% binomial confidence interval (assuming that the number of patients who respond is binomially distributed).
|
Up to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response duration
Time Frame: From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years
|
For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al.
For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years
|
Progression free survival (PFS)
Time Frame: Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years
|
For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al.
For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years
|
Overall survival (OS)
Time Frame: Time from the first dose of the study drug until death, assessed up to 3 years
|
For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al.
For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Time from the first dose of the study drug until death, assessed up to 3 years
|
Rate of objective clinical response (CR, PR) (optional PLCG2 enriched cohort, if activated)
Time Frame: Up to 3 years
|
For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al.
For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Up to 3 years
|
Response duration (optional PLCG2 enriched cohort, if activated)
Time Frame: From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years
|
For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al.
For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years
|
PFS (optional PLCG2 enriched cohort, if activated)
Time Frame: Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years
|
For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al.
For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years
|
OS (optional PLCG2 enriched cohort, if activated)
Time Frame: Time from the first dose of the study drug until death, assessed up to 3 years
|
For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al.
For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Time from the first dose of the study drug until death, assessed up to 3 years
|
Rate of objective clinical response (CR, PR) (MCL cohort)
Time Frame: Up to 3 years
|
Responses are defined according the revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Up to 3 years
|
Response duration (MCL cohort)
Time Frame: From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years
|
Responses are defined according the revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years
|
PFS (MCL cohort)
Time Frame: Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years
|
Responses are defined according the revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years
|
OS (MCL cohort)
Time Frame: Time from the first dose of the study drug until death, assessed up to 3 years
|
Responses are defined according the revised response criteria for malignant lymphoma.
Summarized using standard Kaplan-Meier methods.
|
Time from the first dose of the study drug until death, assessed up to 3 years
|
Incidence of adverse events (AEs), assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 criteria
Time Frame: Up to 30 days post-treatment
|
For each disease group, frequency and severity of adverse events will be collected and summarized by descriptive statistics.
|
Up to 30 days post-treatment
|
Frequency of AEs requiring dose reduction or drug discontinuation
Time Frame: Up to 30 days post-treatment
|
Number of patients who require dose modifications and/or dose delays will be assessed.
|
Up to 30 days post-treatment
|
Number of courses completed
Time Frame: Up to 30 days post-treatment
|
Number of courses started/completed and the reasons for going off-treatment will be assessed.
|
Up to 30 days post-treatment
|
Pharmacodynamic modulation of the downstream targets of the BCR (including LCP1) after sotrastaurin acetate treatment
Time Frame: Baseline to up to course 1 day 29
|
Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships.
Changes in BCR signaling over time may be evaluated quantitatively using repeated measures models and graphically with individual time plots or box plots.
|
Baseline to up to course 1 day 29
|
Pharmacodynamic modulation of the downstream targets of nuclear transcription factor kappa-B after sotrastaurin acetate treatment
Time Frame: Baseline to up to course 1 day 29
|
Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships.
|
Baseline to up to course 1 day 29
|
Pharmacodynamic modulation of downstream targets of WNT/beta-catenin pathway
Time Frame: Baseline to up to course 1 day 29
|
Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships.
|
Baseline to up to course 1 day 29
|
Genomic features associated with response by deep sequencing panel targeted at recurrent mutations in CLL
Time Frame: Up to course 1 day 29
|
Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships.
|
Up to course 1 day 29
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James Blachly, MD, The Ohio State University Wexner Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Leukemia, B-Cell
- Lymphoma
- Leukemia
- Recurrence
- Lymphoma, Mantle-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Prolymphocytic
Other Study ID Numbers
- OSU-14026
- NCI-2014-02002 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- COEB071XUS01T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Mantle Cell Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Central Nervous System Lymphoma | Gastric Mantle Cell Lymphoma | Splenic Mantle Cell LymphomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin LymphomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedIbrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma | Refractory Follicular...United States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); GlaxoSmithKline; Millennium Pharmaceuticals,...TerminatedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Xinqiao Hospital of ChongqingXuzhou Medical University; Shanghai Changzheng Hospital; Hrain Biotechnology...UnknownRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular Lymphoma | Stage...China
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Xinqiao Hospital of ChongqingXuzhou Medical UniversityUnknownRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III/IV Adult Diffuse Large Cell Lymphoma | Stage III/IV Follicular Lymphoma | Stage III/IV Mantle Cell LymphomaChina
Clinical Trials on laboratory biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed